Education
About Us
Working with TipRanks
Follow Us
Thiogenesis Therapeutics Corp (TSE:TTI)
:TTI
Tti-0102: Cysteamine-Pantetheine Disulfide, D-Mannitol
Leigh Syndrome
Phase II
Not Yet Recruiting
A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
May 06, 2025
―
Tti-0102
Melas Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis And Stroke-Like Episodes (Melas)
Phase II
Recruiting
A Study to Assess TTI-0102 vs Placebo in MELAS Patients
Sep 29, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Thiogenesis Therapeutics Corp (TTI) have in its pipeline
TTI is currently developing the following drugs: Tti-0102: Cysteamine-Pantetheine Disulfide, D-Mannitol, Tti-0102. These drug candidates are in various stages of clinical development as the company works toward FDA approval.